GlobeNewswire Clinical StudiesOriginal article
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Phase 3positivedeucrictibantPositive
AI Analysis
Summary
Pharvaris announced publication of Phase 3 RAPIDe-3 study results in The Lancet demonstrating rapid and sustained efficacy of deucrictibant for on-demand treatment of HAE attacks in adolescents and adults. The positive trial results represent a significant milestone for the oral bradykinin B2 receptor antagonist development program.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 RAPIDe-3 study results showing rapid and sustained efficacy in treating HAE attacks published in The Lancet
Importance:7/10
Sentiment:
0.80
Phase 3HAErare diseasedata publicationoral medicationon-demand treatment
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on October 8, 2026 10:35 PM